Pooled Data Favor Short-Course HCV Treatment |
Journal Updates
eMediNexus Coverage from: 
Pooled Data Favor Short-Course HCV Treatment

0 Read Comments                

Eight weeks of glecaprevir-pibrentasvir was found to be efficacious and well tolerated in treatment-naive patients with all hepatitis C virus (HCV) genotype infections, with or without cirrhosis, reported researchers online in Clinical Gastroenterology and Hepatology.

A post-hoc analysis from eight pooled trials involving over 2,300 patients revealed that 8-week treatment with glecaprevir-pibrentasvir was associated with sustained viral response (SVR) rates of 97.6% at 12 weeks in an intent-to-treat population (ITT) and 99.3% in a modified ITT population, irrespective of cirrhotic status… (Medpage Today)

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now